Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies

Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70

(2022) Brian A. Bergmark et al.   CIRCULATION

A Biological Rationale for the Disparate Effects of Omega-3 Fatty Acids on Cardiovascular Disease Outcomes

(2022) Samuel C.R. Sherratt et al.   PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS

Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy

(2022) Paul M Ridker et al.   CIRCULATION

Evinacumab reduces remnant cholesterol in patients with hypercholesterolemia or hypertriglyceridemia

(2022) R.S. Rosenson et al.   ATHEROSCLEROSIS

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

(2022) Aruna Das Pradhan et al.   NEW ENGLAND JOURNAL OF MEDICINE

ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia

(2021) Laurens F. Reeskamp et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction

(2021) Aleesha Shaik et al.   CARDIOVASCULAR DRUGS AND THERAPY

Per-Particle Triglyceride-Rich Lipoproteins Imply Higher Myocardial Infarction Risk Than Low-Density Lipoproteins

(2021) Mia Ø. Johansen et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

(2021) Ioanna Gouni-Berthold et al.   Lancet Diabetes & Endocrinology

Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study

(2021) Renato Quispe et al.   EUROPEAN HEART JOURNAL

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

(2021) Henry N Ginsberg et al.   EUROPEAN HEART JOURNAL

Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction

(2021) Anette Varbo et al.   EUROPEAN HEART JOURNAL

Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia

(2021) Zahid Ahmad et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia

(2021) Salim S. Virani et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis

(2021) Robert J. Sanchez et al.   Lipids in Health and Disease

New Therapies for Lowering Triglyceride-Rich Lipoproteins

(2021) Robert S. Rosenson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Angiopoietin-like protein 3 (ANGPTL3) governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance

(2020) Rene C. Adam et al.   JOURNAL OF LIPID RESEARCH

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans

(2020) Jan Borén et al.   Frontiers in Endocrinology

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

(2020) Daniel Gaudet et al.   EUROPEAN HEART JOURNAL

Evinacumab for Homozygous Familial Hypercholesterolemia

(2020) Frederick J. Raal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Triglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease

(2020) Edward K Duran et al.   CLINICAL CHEMISTRY

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk

(2020) Stephen J. Nicholls et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evinacumab in Patients with Refractory Hypercholesterolemia

(2020) Robert S. Rosenson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease

(2019) Brian A. Ference et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels

(2019) Veronica J Alexander et al.   EUROPEAN HEART JOURNAL

Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia

(2019) Zahid Ahmad et al.   CIRCULATION

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome

(2019) Joseph L. Witztum et al.   NEW ENGLAND JOURNAL OF MEDICINE

APOC3Loss-of-Function Mutations, Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Cardiovascular RiskHighlights

(2018) Anders B. Wulff et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the Treating to New Targets (TNT) Trial

(2018) Antonio J. Vallejo-Vaz et al.   CIRCULATION

Impact of Lipids on Cardiovascular Health

(2018) Brian A. Ference et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus

(2018)   NEW ENGLAND JOURNAL OF MEDICINE

Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer

(2018) JoAnn E. Manson et al.   NEW ENGLAND JOURNAL OF MEDICINE

FISHing for the Miracle of Eicosapentaenoic Acid

(2018) John J.P. Kastelein et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

(2018) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance

(2017) Jorge F. Haller et al.   JOURNAL OF LIPID RESEARCH

ANGPTL3 Deficiency and Protection Against Coronary Artery Disease

(2017) Nathan O. Stitziel et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

(2017) Frederick E. Dewey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease

(2016) Børge G. Nordestgaard   CIRCULATION RESEARCH

Apolipoprotein CIII is a new player in diabetes

(2016) Lisa Juntti-Berggren et al.   CURRENT OPINION IN LIPIDOLOGY

Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease

(2016) Anna Helgadottir et al.   NATURE GENETICS

Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis

(2016) Simon B. Pedersen et al.   JAMA Internal Medicine

Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases

(2015) Fangfang Zhang et al.   MOLECULAR ENDOCRINOLOGY

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

(2015) Daniel Gaudet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease

(2014) Robert S. Rosenson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease

(2014) Anders Berg Jørgensen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting APOC3 in the Familial Chylomicronemia Syndrome

(2014) Daniel Gaudet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus

(2013) Frank M. Sacks et al.   CIRCULATION

Apolipoproteins C-I and C-III Inhibit Lipoprotein Lipase Activity by Displacement of the Enzyme from Lipid Droplets

(2013) Mikael Larsson et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Common variants associated with plasma triglycerides and risk for coronary artery disease

(2013) Ron Do et al.   NATURE GENETICS

Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy

(2012) Samia Mora et al.   CIRCULATION

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

(2011) M. John Chapman et al.   EUROPEAN HEART JOURNAL

Apolipoprotein C-III and the Metabolic Basis for Hypertriglyceridemia and the Dense Low-Density Lipoprotein Phenotype

(2010) Chunyu Zheng et al.   CIRCULATION

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

(2010) Min Jun et al.   LANCET

Exome Sequencing,ANGPTL3Mutations, and Familial Combined Hypolipidemia

(2010) Kiran Musunuru et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection

(2008) T. I. Pollin et al.   SCIENCE

Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies

(2008) Robert S Rosenson et al.   Nature clinical practice. Cardiovascular medicine